A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease

被引:52
作者
Agarwal, Rajiv [1 ,2 ]
Duffin, Kevin L. [3 ]
Laska, Dennis A. [3 ]
Voelker, James R. [3 ]
Breyer, Matthew D. [3 ]
Mitchell, Peter G. [3 ]
机构
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[2] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
albuminuria; biomarkers; chronic kidney disease; ENDOTHELIAL GROWTH-FACTOR; STAGE RENAL-DISEASE; ECONOMIC BURDEN; NEPHROPATHY; RISK; EXPRESSION; MORTALITY;
D O I
10.1093/ndt/gfu255
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Diabetic nephropathy imposes a substantial cardiovascular and renal burden contributing to both morbidity and excess mortality. Progression of chronic kidney disease (CKD) in diabetes mellitus is variable, and few biomarkers are available to predict progression accurately. Identification of novel predictive biomarkers may inform clinical care and assist in the design of clinical trials. We hypothesized that urinary and plasma protein biomarkers predict CKD progression independently of the known clinical markers such as albuminuria and estimated glomerular filtration rate (eGFR) in diabetic nephropathy. We studied 67 US veterans with CKD due to type 2 diabetes mellitus and 20 age-matched controls (no CKD, hypertension or cardiovascular disease). After clinical evaluation and the collection of blood and urine specimens for 24 biomarkers, we followed subjects prospectively for the next 2-6 years. CKD progression was defined in three ways: (i) clinically by examining eGFR versus time plots for each individual (slope progression), (ii) progression to end-stage renal disease (ESRD) and (iii) a composite outcome of ESRD or death. Among 17 urinary and 7 plasma biomarkers evaluated, the relationship of the biomarkers with outcome was as follows: (i) for progression identified by eGFR plots, urinary C-terminal fibroblast growth factor (FGF)-23 emerged to have the strongest primary association (adjusted odds ratio [aOR] 2.08, P = 0.008); (ii) for ESRD, plasma vascular endothelial growth factor (VEGF) had an association (aOR: 1.44, P = 0.027) and (iii) for the composite outcome of death and ESRD, plasma C-terminal FGF-23 also had a robust direct association (aOR: 3.07, P = 0.008). The relationship of biomarkers with future progression of CKD is complex and depends in part on how CKD progression is defined. Biomarkers in the FGF-23 and VEGF-A pathways predicted patient progression independently of albuminuria levels in this patient cohort. Additional studies in other cohorts will help further validate this pilot study.
引用
收藏
页码:2293 / 2302
页数:10
相关论文
共 23 条
[1]   Kidney Disease and Increased Mortality Risk in Type 2 Diabetes [J].
Afkarian, Maryam ;
Sachs, Michael C. ;
Kestenbaum, Bryan ;
Hirsch, Irl B. ;
Tuttle, Katherine R. ;
Hinnmelfarb, Jonathan ;
de Boer, Ian H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02) :302-308
[2]   Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease [J].
Agarwal, Rajiv ;
Bunaye, Zerihun ;
Bekele, Dagim M. ;
Light, Robert P. .
AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (04) :569-575
[3]   Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial [J].
Bakris, George L. ;
Sarafidis, Pantelis A. ;
Weir, Matthew R. ;
Dahlof, Bjorn ;
Pitt, Bertram ;
Jamerson, Kenneth ;
Velazquez, Eric J. ;
Staikos-Byrne, Linda ;
Kelly, Roxzana Y. ;
Shi, Victor ;
Chiang, Yann-Tong ;
Weber, Michael A. .
LANCET, 2010, 375 (9721) :1173-1181
[4]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[5]   The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease [J].
Chaudhary, Kunal ;
Phadke, Gautam ;
Nistala, Ravi ;
Weidmeyer, Charles E. ;
McFarlane, Samy I. ;
Whaley-Connell, Adam .
CURRENT DIABETES REPORTS, 2010, 10 (01) :37-42
[6]   Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States [J].
de Boer, Ian H. ;
Rue, Tessa C. ;
Hall, Yoshio N. ;
Heagerty, Patrick J. ;
Weiss, Noel S. ;
Himmelfarb, Jonathan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (24) :2532-2539
[7]   Chronic Kidney Disease as a Coronary Disease Equivalent-A Comparison with Diabetes over a Decade [J].
Debella, Yalew T. ;
Giduma, Habtamu A. ;
Light, Robert P. ;
Agarwal, Rajiv .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06) :1385-1392
[8]   Biomarkers in chronic kidney disease: a review [J].
Fassett, Robert G. ;
Venuthurupalli, Sree K. ;
Gobe, Glenda C. ;
Coombes, Jeff S. ;
Cooper, Matthew A. ;
Hoy, Wendy E. .
KIDNEY INTERNATIONAL, 2011, 80 (08) :806-821
[9]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[10]   Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study [J].
Fliser, Danilo ;
Kollerits, Barbara ;
Neyer, Ulrich ;
Ankerst, Donna P. ;
Lhotta, Karl ;
Lingenhel, Arno ;
Ritz, Eberhard ;
Kronenberg, Florian .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (09) :2600-2608